Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management

Journal of the American Academy of Dermatology

Volumn 71, Issue 4, 2014, Pages 787-794

  Miller, Kristen K ^a   Gorcey, Loren ^a   McLellan, Beth N ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy complications; Chemotherapy nail complications; Hand foot skin reaction; Hand foot syndrome; Molecular targeted therapy complications; Palmoplantar erythrodysesthesia

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; IDARUBICIN; KERATOLYTIC AGENT; PAZOPANIB; PYRIDOXINE; REGORAFENIB; SKIN CREAM; SORAFENIB; VEMURAFENIB;

CELL DEATH; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG CYTOTOXICITY; EVIDENCE BASED PRACTICE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYDROTHERAPY; HYPERKERATOSIS; INFLAMMATION; KERATINOCYTE; NAIL DISEASE; NAIL PIGMENTATION; NONHUMAN; ONYCHOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WOUND CARE; CHEMICALLY INDUCED DISORDER; CHEMOTHERAPY COMPLICATIONS; CHEMOTHERAPY NAIL COMPLICATIONS; DOSE RESPONSE; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; FEMALE; HAND-FOOT SKIN REACTION; MALE; MOLECULAR TARGETED THERAPY COMPLICATIONS; PALMOPLANTAR ERYTHRODYSESTHESIA; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

CHEMOTHERAPY COMPLICATIONS; CHEMOTHERAPY NAIL COMPLICATIONS; HAND-FOOT SKIN REACTION; HAND-FOOT SYNDROME; MOLECULAR TARGETED THERAPY COMPLICATIONS; PALMOPLANTAR ERYTHRODYSESTHESIA;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; HAND-FOOT SYNDROME; HUMANS; MALE; NAIL DISEASES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84910113008     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.03.019     Document Type: Review

References (45)

1. Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974;148: 90-2.
2. Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002;14:212-6.
3. Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, et al. The hand-foot-syndrome associated with medical tumor therapyeclassification and management. J Dtsch Dermatol Ges 2010;8:652-61.
4. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: incidence, recognition and management. Am J Clin Dermatol 2000;1:225-34.
5. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009;77:257-71.
6. Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, Lacouture ME. Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol 2012;23:2103-8.
7. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991;24:457-61.
8. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008;59:524-9.
9. Farr KP, Safwat A. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 2011;4:229-35.
10. Stubblefield MD, Custodio CM, Kaufmann P, Dickler MN. Small-fiber neuropathy associated with capecitabine (Xeloda)-induced hand-foot syndrome: a case report. J Clin Neuromuscul Dis 2006;7:128-32.
11. Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 2011; 16:1469-78.
12. Hoesly FJ, Baker SG, Gunawardane ND, Cotliar JA. Capecitabineinduced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature. Arch Dermatol 2011;147:1418-23.
13. von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 2008;44:781-90.
14. National Cancer Institute. Common Terminology Criteria for Adverse Events v4. 0. NCI, NIH, DHHS. May 29, 2009 NIH publication # 09-7473.
15. Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, et al. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. Biol Pharm Bull 2012;35:717-24.
16. Wong M, Choo SP, Tan EH. Travel warning with capecitabine. Ann Oncol 2009;20:1281.
17. Martschick A, Sehouli J, Patzelt A, Richter H, Jacobi U, Oskay-Ozcelik G, et al. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res 2009;29:2307-13.
18. Yokomichi N, Nagasawa T, Coler-Reilly A, Suzuki H, Kubota Y, Yoshioka R, et al. Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin. Hum Cell 2013;26:8-18.
19. Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15: 1411-6.
20. Milano G, Etienne-Grimaldi MC, Mari M, Lassalle S, Formento JL, Francoual M, et al. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008;66:88-95.
21. Caronia D, Martin M, Sastre J, de la Torre J, Garca-Saenz JA, Alonso MR, et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res 2011;17:2006-13.
22. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006;12:5491-5.
23. Saif MW. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf 2011;10:159-69.
24. Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2013; 31:787-97.
25. Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L, et al. A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma [abstract]. J Clin Oncol 2012 (suppl).
26. Ruhstaller T, Ribi K, Sun H, Schmitz S, Borner M, Winkler A, et al. Prevention of palmoplantar erythrodysesthesia (PPE) with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (PLD), a placebo-controlled, double blinded, phase III trial (SAKK 92/08) [abstract]. J Clin Oncol 2012 (suppl).
27. Mangili G, Petrone M, Gentile C, De Marzi P, Vigano R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 2008;108:332-5.
28. Scotte F, Banu E, Medioni J, Levy E, Ebenezer C, Marsan S, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 2008;112:1625-31.
29. Scotte F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005;23:4424-9.
30. Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, et al. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 2012;23:1348-53.
31. Corrie PG, Bulusu R, Wilson CB, Armstrong G, Bond S, Hardy R, et al. A randomized study evaluating the use of pyridoxine to avoid capecitabine dose modifications. Br J Cancer 2012;107: 585-7.
32. Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 2010;28: 3824-9.
33. von Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, Eaton S, et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 2010;116:4735-43.
34. Li JR, Yang CR, Cheng CL, Ho HC, Chiu KY, Su CK, et al. Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions. Support Care Cancer 2013;21:907-11.
35. Childress J, Lokich J. Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol 2003; 26:435-6.
36. Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 2003;14:333-7.
37. Winther D, Saunte DM, Knap M, Haahr V, Jensen AB. Nail changes due to docetaxelea neglected side effect and nuisance for the patient. Support Care Cancer 2007;15:1191-7.
38. Wasner G, Hilpert F, Baron R, Pfisterer J. Clinical picture: nail changes secondary to docetaxel. Lancet 2001;357:910.
39. Borecky DJ, Stephenson JJ, Keeling JH, Vukelja SJ. Idarubicin-induced pigmentary changes of the nails. Cutis 1997;59:203-4.
40. Giacobetti R, Esterly NB, Morgan ER. Nail hyperpigmentation secondary to therapy with doxorubicin. Am J Dis Child 1981; 135:317-8.
41. Peuvrel L, Bachmeyer C, Reguiai Z, Bachet JB, Andre T, Bensadoun RJ, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer 2012;20:909-21.
42. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31.
43. Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2012;30:1773-81.
44. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12.
45. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013;24:1691-7.